Case Reports Open access

Membranous nephropathy in a patient with Sjögren’s disease

Authors

Published
20 May 2025
Section
Case Reports

Abstract

Sjögren’s disease (SjD) was first described in a middle-aged female patient with chronic rheumatism in 1930. Membranous nephropathy (MN) is the most commonly identified type of glomerulonephritis in older adults with nephrotic syndrome. One of the autoimmune diseases that causes secondary MN is SjD. A 68-year-old female patient with a medical history of 25 years of hypertension, 9 years of SjD, depressive mood disorder, and intracoronary stent placement applied with peripheral edema. Hypoalbuminemia, hypothyroidism, hematuria, proteinuria, and albuminuria were also detected. In the autoantibody panel, antinuclear antibodies, anti-Ro-52 antibody, anti-Ro/SS-related antigen A antibody, and anticentromere antibody were positive. Kidney biopsy revealed MN. Anti-phospholipase A2 receptor antibody was negative. Methylprednisolone, cyclosporine, hydroxychloroquine, nifedipine, metoprolol, valsartan, L-thyroxine, acetylsalicylic acid, artificial tear drops, and fluoxetine were administered. Partial remission was detected in the first month of treatment. However, the patient, who had all vaccinations, developed swine flu infection and subsequently widespread candidiasis, and despite amphotericin B treatment and discontinuation of immunosuppressives, died in the fifth month due to septic shock. Anti-PLA2R antibody negative MN is one of the kidney manifestations of SjD. The poor prognosis of our patient was due to high SjD disease activity and severe infectious complications, which are independent risk factors for overall mortality.

References

  1. Murube J. Henrik Sjögren, 1899-1986. Ocul Surf 2010; 8: 2-7. DOI: https://doi.org/10.1016/S1542-0124(12)70212-4
  2. Nair JJ, Singh TP. Sjögren's syndrome: review of the aetiology, pathophysiology & potential therapeutic interventions. J Clin Exp Dent 2017; 9: e584-9. DOI: https://doi.org/10.4317/jced.53605
  3. Chen R, Wang J, Xie Q, Xue J, Hao C. Sjögren's syndrome complicated with membranous nephropathy, a cause or coincidence? Int J Rheum Dis 2021; 24: 1086-94. DOI: https://doi.org/10.1111/1756-185X.14168
  4. Yang HX, Wang J, Wen YB, Fei YY, Jiang MD, Zhou MY, et al. Renal involvement in primary Sjögren's syndrome: a retrospective study of 103 biopsy-proven cases from a single center in China. Int J Rheum Dis 2018; 21: 223-9. DOI: https://doi.org/10.1111/1756-185X.13182
  5. Seror R, Bowman SJ, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A, et al. EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. RMD Open 2015; 1: e000022. DOI: https://doi.org/10.1136/rmdopen-2014-000022
  6. Jurubiță R, Obrișcă B, Achim C, Micu G, Sorohan B, Bobeică R, et al. Anti-phospholipase A2 receptor antibody screening in nephrotic syndrome may identify a distinct subset of patients with primary membranous nephropathy. Int Urol Nephrol 2022; 54: 1713-23. DOI: https://doi.org/10.1007/s11255-021-03061-9
  7. Negrini S, Emmi G, Greco M, Borro M, Sardanelli F, Murdaca G, et al. Sjögren's syndrome: a systemic autoimmune disease. Clin Exp Med 2022; 22: 9-25. DOI: https://doi.org/10.1007/s10238-021-00728-6
  8. Baer AN. Diagnosis and classification of Sjögren’s syndrome. 2024. Available from: https://www.uptodate.com/contents/diagnosis-and-classification-of-sjogrens-disease? Accessed on: 14/03/2024.
  9. Retamozo S, Baldini C, Bootsma H, De Vita S, Dörner T, Fisher BA, et al. Therapeutic recommendations for the management of older adult patients with Sjögren's syndrome. Drugs Aging 2021; 38: 265-84. DOI: https://doi.org/10.1007/s40266-021-00838-6
  10. Baer AN. Clinical manifestations of Sjögren's disease: extraglandular disease. 2024. Available from: https://www.uptodate.com/contents/clinical-manifestations-of-sjogrens-disease-extraglandular-disease? Accessed on: 26/03/2024.
  11. Qiu DD, Li Z, Wang JJ, Chen DQ, Tu YM, Liang SS, et al. The spectrum and prognosis of Sjögren's syndrome with membranous nephropathy. Clin Kidney J 2024; 18: sfae384. DOI: https://doi.org/10.1093/ckj/sfae384
  12. Aiyegbusi O, McGregor L, McGeoch L, Kipgen D, Geddes CC, Stevens KI. Renal disease in primary Sjögren’s syndrome. Rheumatol Ther 2021; 8: 63-80. DOI: https://doi.org/10.1007/s40744-020-00264-x
  13. Radhakrishnan J. Kidney disease in primary Sjögren's disease. 2024. Available from: https://www.uptodate.com/contents/kidney-disease-in-primary-sjogrens-disease? Accessed on: 26/03/2024.
  14. Chatterjee R, Balakrishnan A, Kharbanda R, Rathore U, Gupta L, Misra DP, et al. Renal involvement in Sjőgren's syndrome: predictors and impact on patient outcomes. Rheumatol Int 2023; 43: 1297-306. DOI: https://doi.org/10.1007/s00296-022-05242-w
  15. Alsharhan L, Beck LH Jr. Membranous nephropathy: core curriculum 2021. Am J Kidney Dis 2021; 77: 440-53. DOI: https://doi.org/10.1053/j.ajkd.2020.10.009
  16. Goules AV, Tatouli IP, Moutsopoulos HM, Tzioufas AG. Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome. Arthritis Rheum 2013; 65: 2945-53. DOI: https://doi.org/10.1002/art.38100
  17. Utomo SW, Putri JF. Infections as risk factor of Sjögren's syndrome. Open Access Rheumatol 2020; 12: 257-66. DOI: https://doi.org/10.2147/OARRR.S276727
  18. Brito-Zerón P, Flores-Chávez A, Horváth IF, Rasmussen A, Li X, Olsson P, et al. Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study. EClinicalMedicine 2023; 61: 102062. DOI: https://doi.org/10.1016/j.eclinm.2023.102062
  19. Guo L, Zhao S, Liu X. Development of a nomogram for membranous nephropathy prediction in patients with primary Sjögren's syndrome: a 6-year retrospective study. Front Immunol 2024; 15: 1320880. DOI: https://doi.org/10.3389/fimmu.2024.1320880

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.